221 related articles for article (PubMed ID: 7249422)
1. Measurement of fibrinopeptide A in the evaluation of heparin activity and fibrin formation during hemodialysis.
Wilhelmsson S; Asaba H; Gunnarsson B; Kudryk B; Robinson D; Bergström J
Clin Nephrol; 1981 May; 15(5):252-8. PubMed ID: 7249422
[TBL] [Abstract][Full Text] [Related]
2. The effects of three different heparin regimes on heparin concentrations in plasma and fibrin formation in dialyzers.
Gunnarsson B; Asaba H; Dawidson S; Wilhelmsson S; Bergström J
Clin Nephrol; 1981 Mar; 15(3):135-42. PubMed ID: 7273488
[TBL] [Abstract][Full Text] [Related]
3. Hemodialysis and heparin. Alternative methods of measuring heparin and of detecting activation of coagulation.
Ireland HA; Boisclair MD; Lane DA; Thompson E; Curtis JR
Clin Nephrol; 1991 Jan; 35(1):26-33. PubMed ID: 1826095
[TBL] [Abstract][Full Text] [Related]
4. Objective assessment of heparin requirements for hemodialysis in humans.
Ireland H; Lane DA; Curtis JR
J Lab Clin Med; 1984 Apr; 103(4):643-52. PubMed ID: 6230409
[TBL] [Abstract][Full Text] [Related]
5. Whole-blood activated coagulation time for evaluation of heparin activity during hemodialysis: a comparison of administration by single-dose and by infusion.
Wilhelmsson S; Lins LE
Clin Nephrol; 1983 Feb; 19(2):82-6. PubMed ID: 6839556
[TBL] [Abstract][Full Text] [Related]
6. [Intracranial hemorrhage and hemostasis. Monitoring patients after intracranial hemorrhage by determination and follow-up of activation products of blood coagulation].
Menges T; von Lessen A; Welters I; Wagner RM; Ruwoldt R; Boldt J; Hempelmann G
Infusionsther Transfusionsmed; 1994 Aug; 21(4):244-50. PubMed ID: 7950289
[TBL] [Abstract][Full Text] [Related]
7. Prothrombin fragment 1 + 2, thrombin-antithrombin III-complexes and fibrinopeptide A in spontaneously clotting whole blood in vitro. Effects of heparin addition and antithrombin III deficiency.
Herren T; Straub PW; Haeberli A
Thromb Haemost; 1994 Jan; 71(1):49-53. PubMed ID: 8165646
[TBL] [Abstract][Full Text] [Related]
8. A single dose of a low molecular weight heparin fragment for anticoagulation during hemodialysis.
Ljungberg B; Blombäck M; Johnsson H; Lins LE
Clin Nephrol; 1987 Jan; 27(1):31-5. PubMed ID: 3815906
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of fibrinopeptide A generation tests in experimental and clinical studies with low molecular weight heparin fractions.
Emanuele RM; Fareed J; Walenga JM; Hoppensteadt DA; Baker WH
Semin Thromb Hemost; 1985 Apr; 11(2):121-8. PubMed ID: 4035363
[TBL] [Abstract][Full Text] [Related]
10. The generation of fibrinopeptide A in clinical blood samples: evidence for thrombin activity.
Nossel HL; Ti M; Kaplan KL; Spanondis K; Soland T; Butler VP
J Clin Invest; 1976 Nov; 58(5):1136-44. PubMed ID: 993337
[TBL] [Abstract][Full Text] [Related]
11. Intraperitoneal fibrin-formation and its inhibition in CAPD.
Gries E; Paar D; Graben N; Bock KD
Clin Nephrol; 1986 Oct; 26(4):209-12. PubMed ID: 3780071
[TBL] [Abstract][Full Text] [Related]
12. Measurement of fibrinopeptide A in human blood.
Nossel HL; Yudelman I; Canfield RE; Butler VP; Spanondis K; Wilner GD; Qureshi GD
J Clin Invest; 1974 Jul; 54(1):43-53. PubMed ID: 4600045
[TBL] [Abstract][Full Text] [Related]
13. High fibrinopeptide A (FPA) levels in acute non-lymphocytic leukemia are reduced by heparin administration.
Gugliotta L; Viganò S; D'Angelo A; Guarini A; Tura S; Mannucci PM
Thromb Haemost; 1984 Dec; 52(3):301-4. PubMed ID: 6531754
[TBL] [Abstract][Full Text] [Related]
14. Sequence of release of fibrinopeptide A from fibrinogen molecules by thrombin or Atroxin.
Meh DA; Siebenlist KR; Bergtrom G; Mosesson MW
J Lab Clin Med; 1995 Mar; 125(3):384-91. PubMed ID: 7897305
[TBL] [Abstract][Full Text] [Related]
15. Improved dialyzer reuse after use of a population pharmacodynamic model to determine heparin doses.
Ouseph R; Brier ME; Ward RA
Am J Kidney Dis; 2000 Jan; 35(1):89-94. PubMed ID: 10620549
[TBL] [Abstract][Full Text] [Related]
16. Haemodialysis with low MW heparin: dosage requirements for the elimination of extracorporeal fibrin formation.
Lane DA; Ireland H; Flynn A; Anastassiades E; Curtis JR
Nephrol Dial Transplant; 1986; 1(3):179-87. PubMed ID: 2955253
[TBL] [Abstract][Full Text] [Related]
17. Relationship between fibrinopeptide A and fibrinogen/fibrin fragment E in thromboembolism, DIC and various non-thromboembolic diseases.
Mombelli G; Monotti R; Haeberli A; Straub PW
Thromb Haemost; 1987 Aug; 58(2):758-63. PubMed ID: 3672428
[TBL] [Abstract][Full Text] [Related]
18. Long-term effects of erythropoietin treatment on the coagulation system during standardized hemodialysis.
Clyne N; Lins LE; Egberg N
Clin Nephrol; 1995 Apr; 43(4):260-7. PubMed ID: 7606881
[TBL] [Abstract][Full Text] [Related]
19. Effects of a low molecular weight heparin (Fragmin) and of unfractionated heparin on coagulation activation at the site of plug formation in vivo.
Eichinger S; Wolz M; Nieszpaur-Los M; Schneider B; Lechner K; Eichler HG; Kyrle PA
Thromb Haemost; 1994 Dec; 72(6):831-5. PubMed ID: 7740450
[TBL] [Abstract][Full Text] [Related]
20. [Significance of fibrinopeptide A as an indicator for coagulative analysis in thrombotic diseases].
Murakoshi T
Hokkaido Igaku Zasshi; 1982 May; 57(3):351-63. PubMed ID: 6957368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
